Search

Memorial Sloan Kettering physicians have experience and specialized expertise in caring for people with uncommon cancers.

Thetis cells, a class of immune cells first described by MSK researchers in 2022, play an essential and previously unknown role in suppressing inflammatory responses to food, a new study finds.

The FDA has approved the targeted drug repotrectinib for patients 12 and older with tumors that carry gene changes called NTRK fusions. The trial that resulted in the approval was led by MSK investigators.

A prostate-specific antigen (PSA) test taken for the first time between the ages of 44 and 50 can predict the likelihood that a man will die from prostate cancer over the next 25 to 30 years, according to researchers at Memorial Sloan Kettering Cancer Center.

Pituitary adenomas continue to grow in a small subset of patients despite treatment with standard surgery and radiotherapy. Recognizing the significant unmet needs in this cohort, we recently published a review of the latest treatment options.

Learn more about world-class cancer care on Long Island at MSK Nassau.

A new approach for treating melanoma combines the immunotherapy drug ipilimumab with chemotherapy that treats only the area affected by cancer.

Our recent research demonstrates that the thrombopoietin receptor agonist romiplostim effectively modifies chemotherapy-induced thrombocytopenia (CIT) in solid tumor patients, allowing a majority to resume chemotherapy